Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.
An upcoming small biotech focused on IO targets with their novel platform approach
On launched products, armored CARs and the potential threat from China
On targeting immunosuppression and some obscure oncogenic targets
Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?
Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...
One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…
We explore the importance of looking under the hood at various expression levels...
4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers
A look at path to market strategies open to a small biotech in the CAR-T cell space
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?
Answering questions on the 1L NSCLC data presented at #AACR18
A look at the latest 1L NSCLC trial readouts
A look at the Class of 2018 new products in development - a hit or miss?
A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.
How can we improve on monotherapy with PARP inhibitors?
How do we address primary and acquired resistance?
Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?
Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?
A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination
What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?
An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.
A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC
Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area